124 related articles for article (PubMed ID: 27266990)
1. Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs.
Gynther M; Pickering DS; Spicer JA; Denny WA; Huttunen KM
Mol Pharm; 2016 Jul; 13(7):2484-91. PubMed ID: 27266990
[TBL] [Abstract][Full Text] [Related]
2. Hemocompatible L-Type amino acid transporter 1 (LAT1)-Utilizing prodrugs of perforin inhibitors can accumulate into the pancreas and alleviate inflammation-induced apoptosis.
Tampio J; Markowicz-Piasecka M; Huttunen KM
Chem Biol Interact; 2021 Aug; 345():109560. PubMed ID: 34153225
[TBL] [Abstract][Full Text] [Related]
3. Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival.
Tampio J; Huttunen J; Montaser A; Huttunen KM
Mol Neurobiol; 2020 Nov; 57(11):4563-4577. PubMed ID: 32754897
[TBL] [Abstract][Full Text] [Related]
4. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
5. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
6. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
8. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
Gynther M; Peura L; Vernerová M; Leppänen J; Kärkkäinen J; Lehtonen M; Rautio J; Huttunen KM
Neurochem Res; 2016 Oct; 41(10):2797-2809. PubMed ID: 27412117
[TBL] [Abstract][Full Text] [Related]
9. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
10. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
Huttunen KM; Huttunen J; Aufderhaar I; Gynther M; Denny WA; Spicer JA
Int J Pharm; 2016 Feb; 498(1-2):205-16. PubMed ID: 26705152
[TBL] [Abstract][Full Text] [Related]
11. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
Montaser AB; Järvinen J; Löffler S; Huttunen J; Auriola S; Lehtonen M; Jalkanen A; Huttunen KM
ACS Chem Neurosci; 2020 Dec; 11(24):4301-4315. PubMed ID: 33228353
[TBL] [Abstract][Full Text] [Related]
12. Brain uptake of ketoprofen-lysine prodrug in rats.
Gynther M; Jalkanen A; Lehtonen M; Forsberg M; Laine K; Ropponen J; Leppänen J; Knuuti J; Rautio J
Int J Pharm; 2010 Oct; 399(1-2):121-8. PubMed ID: 20727958
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
[TBL] [Abstract][Full Text] [Related]
14. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
Gynther M; Laine K; Ropponen J; Leppänen J; Mannila A; Nevalainen T; Savolainen J; Järvinen T; Rautio J
J Med Chem; 2008 Feb; 51(4):932-6. PubMed ID: 18217702
[TBL] [Abstract][Full Text] [Related]
15. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
Ylikangas H; Malmioja K; Peura L; Gynther M; Nwachukwu EO; Leppänen J; Laine K; Rautio J; Lahtela-Kakkonen M; Huttunen KM; Poso A
ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.
Chen W; Yang JZ; Andersen R; Nielsen LH; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):849-57. PubMed ID: 12388672
[TBL] [Abstract][Full Text] [Related]
17. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
Ylikangas H; Peura L; Malmioja K; Leppänen J; Laine K; Poso A; Lahtela-Kakkonen M; Rautio J
Eur J Pharm Sci; 2013 Feb; 48(3):523-31. PubMed ID: 23228412
[TBL] [Abstract][Full Text] [Related]
19. Improved l-Type amino acid transporter 1 (LAT1)-mediated delivery of anti-inflammatory drugs into astrocytes and microglia with reduced prostaglandin production.
Tampio J; Löffler S; Guillon M; Hugele A; Huttunen J; Huttunen KM
Int J Pharm; 2021 May; 601():120565. PubMed ID: 33812973
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen.
Fan W; Wu Y; Li XK; Yao N; Li X; Yu YG; Hai L
Eur J Med Chem; 2011 Sep; 46(9):3651-61. PubMed ID: 21641697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
